Xlife Sciences Ltd.

As of December 31, 2025, Xlife Sciences Ltd. carries a market capitalization of 142.46M, placing it among publicly traded companies globally. Its enterprise value stands at 287.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Xlife Sciences Ltd. has 5.77M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Xlife Sciences Ltd. maintains a current ratio of 0.10, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities.

As of the close on October 23, 2026, Xlife Sciences Ltd.'s stock has declined approximately 56.16% over the past 52 weeks. The 50-day moving average sits at 11.96, while the 200-day moving average is 18.76.

As of December 31, 2025, Xlife Sciences Ltd. holds 1.05M in cash and equivalents against 60.00M in total debt, resulting in a net debt position of 59.48M. Total book value stands at 286.53M, with working capital of -13.38M providing operational flexibility.